AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

At the American College of Cardiology’s 74th Annual Scientific Session in Chicago, results from a study by Fretz et al., ...

medications among women with cardiovascular risk factors, she told the ACC audience. WARRIOR had been limited to female participants because women are disproportionately affected by INOCA ...

A new analysis presented at the ACC 2025 meeting also finds that the new prices for heart failure drugs negotiated through Medicare will reduce hospitalizations. More Medicare Part D patients will ...

Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers ...

However, multiple studies have shown that patients experiencing cardiogenic shock caused by a heart attack who were treated temporarily with an IABP fared no better than similar patients who were ...

Drugs from Ionis and Arrowhead Pharma that block ... and ultra-rare disorder familial chylomicronaemia syndrome (FCS). At ACC, Ionis reported results from the phase 3 BALANCE trial of its ...

While ChatGPT consistently produced responses that were factually correct in many cases, experts unanimously agreed that the ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.